A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
They were supported by the 123rd Special Tactics Squadron, 173rd Airborne Brigade and several companies of 2nd Battalion, 14th Infantry Regiment, 10th Mountain Division. The original plan called for TF Viking to support the 4th Infantry Division advance from Turkey towards Baghdad but the mission was cancelled when Turkey denied staging rights to the US. Viking was assigned the task of keeping 13 Iraqi armoured and infantry divisions in the north from reinforcing Baghdad, the 10th SFG was to organise the Kurdish Peshmerga to support them. Just as in Afghanistan, SF were the first military units in Iraq after the initial entry of JSOC (Joint Special Operations Command) and the CIA. At H-Hour, Bravo and Charlie companies of 1st Battalion, 5th SFG, crossed the Kuwait border began carrying out operations in western Iraq – joining up with the British and Australian SAS and Delta Force elements to secure H-3 Air Base, as well as securing Ar Rutbah; the 5th SFG also carried out operations in support of forces moving on Karbala Nasiriyah and Al Diwaniyah. On 21 March, ODA 554 of Charlie Company, 2nd Battalion 5th SFG entered Iraq and began carrying out operations in southern Iraq – mainly supporting British forces in the seizure of Basra and surrounding locations, until relieved by G squadron, 22 SAS Regiment.
13B Cannon Crewmember 13E Fire Direction Specialist (Cannon Artillery) Later consolidated into 13B 13F Fire Support Specialist 13J Fire Control Specialist (Formerly 13P and 13D) 13M Multiple Launch Rocket System/High Mobility Artillery Rocket System Crewmember 13R Field Artillery Firefinder Radar Operator 13T Field Artillery Surveyor/Meteorological Crewmember 13U Field Artillery Recruit 13Z Field Artillery Senior Sergeant/Sergeant Major
Each metabolic pathway consists of a series of biochemical reactions that are connected by their intermediates: the products of one reaction are the substrates for subsequent reactions, and so on. Metabolic pathways are often considered to flow in one direction. Although all chemical reactions are technically reversible, conditions in the cell are often such that it is thermodynamically more favorable for flux to proceed in one direction of a reaction. For example, one pathway may be responsible for the synthesis of a particular amino acid, but the breakdown of that amino acid may occur via a separate and distinct pathway. One example of an exception to this "rule" is the metabolism of glucose. Glycolysis results in the breakdown of glucose, but several reactions in the glycolysis pathway are reversible and participate in the re-synthesis of glucose (gluconeogenesis).
You can't ask for much more from one of the definitive records of the 2000s." "No question about it," writes George Lang for NewsOK, "2002's “Mclusky Do Dallas” was the most hilarious record the Pixies never made, an album built from lacerating music and equally serrated wit that was custom-built for furious road trips and decibel therapy." Phoenix New Times ranked it third on their list of "10 Underrated Punk Albums That Should Be Considered Classics", with Tom Reardon writing: "Like the first two records on this list [Frankenchrist and Worlds Apart], this is a great record from a great band, but it has been largely ignored by way too many people. Sure, it's noisy and disrespectful to just about anyone with a shred of pop sensibility, but it also totally rocks."
=== Obesity and overweight adults === In 2019 a systematic review compared the effects on weight of various doses of fluoxetine (60 mg/d, 40 mg/d, 20 mg/d, 10 mg/d) in obese and overweight adults. When compared to placebo, all dosages of fluoxetine appeared to contribute to weight loss but lead to increased risk of experiencing side effects, such as dizziness, drowsiness, fatigue, insomnia, and nausea, during the period of treatment. However, these conclusions were from low-certainty evidence. When comparing, in the same review, the effects of fluoxetine on the weight of obese and overweight adults, to other anti-obesity agents, omega-3 gel capsule and not receiving treatment, the authors could not reach conclusive results due to poor quality of evidence.
Sources: en.wikipedia.org
=== First House passage === Following markups by various House committees on their relevant portions of the bill, the House Budget Committee met on May 16, 2025, to combine the various markups into a single reconciliation bill. Some fiscally conservative Republicans opposed the bill over a desire for greater spending cuts, and the bill was rejected in a 21–16 vote, with representatives Chip Roy of Texas, Ralph Norman of South Carolina, Andrew Clyde of Georgia, and Josh Brecheen of Oklahoma joining all Democratic committee members to vote against it. Republican Lloyd Smucker of Pennsylvania changed his vote from yes to no so that he would be allowed to bring a motion to reconsider the bill at a later time. On May 18, the Budget Committee voted to advance the bill in a 17–16 vote. Roy, Norman, Clyde, and Brecheen changed their votes to present after House Republican leadership agreed to make Medicaid work requirements—previously scheduled to begin in 2029—kick in sooner and decrease future subsidies for clean energy. Despite this, the four Republicans said they would not support the bill's final passage unless more changes were made. Republicans did not secure these votes until May 21, when the bill was amended. On the morning of May 22, the United States House of Representatives passed OBBBA by a vote of 215–214–1, mostly along party lines. Fiscally conservative Republicans Thomas Massie and Warren Davidson broke from their party to vote against the bill. Freedom Caucus chair Andy Harris of Maryland voted present.
== Privacy and security concerns == Privacy concerns have been brought up regarding the app. TikTok's privacy policy lists that the app collects usage information, IP addresses, a user's mobile carrier, unique device identifiers, keystroke patterns, and location data, among other data. Other information collected includes users inferred interests based on the content they view as well as content created by users. TikTok is also able to track information about web users even if they are not users of the TikTok app. It collects information such as IP address, online browsing habits and web search history. TikTok can share data with its corporate group, including ByteDance. The company says that it employs access control and approval process overseen by a US-based team. In June 2021, TikTok updated its privacy policy to include potential collection of biometric data, including "faceprints and voiceprints", for special effects and other purposes. The terms said that user authorization would be requested if local law demands such. Experts considered them to be "vague" and their implications "problematic" for the United States due to the country's general lack of robust data privacy laws. In a November 2022 update to its European privacy policy, TikTok stated that its global corporate group employees from China and other countries could gain remote access to the user information of accounts from Europe based on "demonstrated need".
==== Sucrase ==== Function: Sucrase is a stomachs related protein that mobilizes hydrolysis to convert sucrose into glucose and fructose. Clinical Significance: Low amounts of Sucrose also known as Sucrose intolerance happens when sucrose isn't being discharged in the small digestive tract. A result of this is extra gas.
The parenteral route is any route that is not enteral (par- + enteral). Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe, or by the insertion of an indwelling catheter. Locations of application of parenteral administration include:
== Co-crystal structures == iPGM apo structures (2) and five ipglycermide co-crystal structures have been determined by the Protein Structure and X-ray Crystallography Laboratory (PSXL) of Dr. Scott Lovell at the University of Kansas (PDB IDs):
Sources: en.wikipedia.org
The κ-opioid receptor or kappa opioid receptor, abbreviated KOR or KOP for its ligand ketazocine, is a G protein-coupled receptor that is encoded by the OPRK1 gene in humans. The KOR is coupled to the G protein Gi/G0 and is among related receptors that bind opioid-like compounds in the brain and are responsible for mediating the effects of these compounds. These include altering nociception, mood, reward system, and motor control. KOR is one of the two opioid receptors that bind dynorphin opioid peptides as the primary endogenous ligands, the other being newly deorphanized GPR139 receptor. In addition, oxytocin was found to be a positive allosteric modulator of KOR, and a variety of natural alkaloids, terpenoids, and synthetic ligands bind to the receptor. Dysregulation of this receptor system has been implicated in multiple psychiatric disorders including: depressive and anxiety disorders, disorders of diminished motivation, schizophrenia, borderline personality disorder, bipolar disorder, and substance use disorder. Ligands binding to the receptor have been approved to treat pruritus and manage pain. Aside from those indications they are investigated for various psychiatric disorders, irritable bowel syndrome, and acute stroke.
3-Allylfentanyl is an opioid analgesic that is an analogue of fentanyl. 3-Allylfentanyl has effects similar to fentanyl, although it is only 0.13x-0.14x as potent by weight. The decreased potency of this analogue caused by the addition of the allyl group makes it somewhat less dangerous than fentanyl itself (ED50(rat) of 80μg/kg vs 11μg/kg for fentanyl), although this is relative. For comparison, carfentanil is at least 20-30x as potent as fentanyl.
is obtained. Note, however, that all published dissociation constant values refer to the specific ionic medium used in their determination and that different values are obtained with different conditions, as shown for acetic acid in the illustration above. When published constants refer to an ionic strength other than the one required for a particular application, they may be adjusted by means of specific ion theory (SIT) and other theories.
The corporate office has had a few locations, and previously maintained an office at 2516 Via Tejon in Palos Verdes, then at 2424 Moreton Street in Torrance before settling into Irvine (at 17901 Von Karman Avenue) in 1976.
== Toxicity == There has been very little mention of toxicity in most published animal studies using Colostrinin, which may suggest that it exhibits low toxicity. Generally, treatment with Colostrinin in clinical studies has been well tolerated by both animals and humans, with any side-effects being mild and transient.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.